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ABSTRACT		
Background:	Effective	allocation	of	limited	donor	lungs	in	cystic	fibrosis	(CF)	requires	accurate	survival	predictions,	so	that	high-risk	patients	may	be	prioritized	for	transplantation.	In	practice,	decisions	about	allocation	are	made	dynamically,	using	routinely	updated	assessments.	We	present	a	novel	tool	for	evaluating	risk	prediction	models	that,	unlike	traditional	methods,	captures	the	dynamic	nature	of	decision-making.	
Methods:		Predicted	risk	is	used	as	a	score	to	rank	incident	deaths	versus	patients	who	survive,	with	the	goal	of	ranking	the	deaths	higher.	The	mean	rank	across	deaths	at	a	given	time	measures	time-specific	predictive	accuracy;	when	assessed	over	time,	it	reflects	time-varying	accuracy.	
Results:	Applying	this	approach	to	CF	Registry	data	on	patients	followed	from	1993-2011,	we	show	that	traditional	methods	do	not	capture	the	performance	of	models	used	dynamically	in	the	clinical	setting.	Previously	proposed	multivariate	risk	scores	perform	no	better	than	forced	expiratory	volume	in	1	second	as	a	percentage	of	predicted	normal	(FEV1%)	alone.	Despite	its	value	for	survival	prediction,	FEV1%	has	a	low	sensitivity	of	45%	over	time	(for	fixed	specificity	of	95%),	leaving	room	for	improvement	in	prediction.	Finally,	prediction	accuracy	with	annually-updated	FEV1%	shows	minor	differences	compared	to	FEV1%	updated	every	2	years,	which	may	have	clinical	implications	regarding	the	optimal	frequency	of	updating	clinical	information.	
Conclusions:	It	is	imperative	to	continue	to	develop	models	that	accurately	predict	survival	in	CF.	Our	proposed	approach	can	serve	as	the	basis	for	evaluating	the	predictive	ability	of	these	models	by	better	accounting	for	their	dynamic	clinical	use.			
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INTRODUCTION	Lung	transplantation	has	been	shown	to	improve	survival	for	some	cystic	fibrosis	(CF)	patients	whose	disease	is	no	longer	amenable	to	more	conventional	medical	therapies.1,2	However,	due	to	a	shortage	of	donor	lungs,	a	large	number	of	wait-list	patients	die	while	awaiting	transplantation	employing	the	current	allocation	system	in	the	US.	In	2010-2012,	the	wait-list	mortality	rate	was	15.4	per	100	wait-list	years.	Candidates	aged	12-17	years	had	the	highest	wait-list	mortality,	at	19.7	deaths	per	100	wait-list	years,	followed	by	those	aged	18-34	years	at	approximately	18.5	deaths	per	100	wait-list	years.1		Despite	an	increase	in	the	rate	of	lung	transplants	over	the	past	decade,	wait-list	mortality	rates	continue	to	rise.3	Accurate	predictions	of	mortality	are	necessary	so	that	limited	donor	lungs	may	be	prioritized	to	patients	who	are	at	the	greatest	risk	of	death	without	transplantation.	The	goal	is	to	use	a	patient’s	clinical	characteristics	to	calculate	the	predicted	risk	of	mortality	within	a	specified	time	period	and	to	rank	or	classify	patients	on	the	wait-list	as	those	who	are	predicted	to	die	soon	versus	those	who	are	not.		Although	forced	expiratory	volume	in	1	second	as	a	percentage	of	predicted	normal	(FEV1%)	is	a	standard	measure	of	pulmonary	function	used	for	assessing	patient	prognosis	and	recommending	lung	transplantation,	its	accuracy	has	been	questioned.4-6	Several	risk	prediction	(or	prognostic)	models	combining	FEV1%	with	other	clinical	factors	have	been	proposed;	however,	it	is	unclear	how	accurate	these	models	are,	since	their	evaluation	has	failed	to	address	classification	accuracy	and	instead	focused	solely	on	measures	of	model	fit	or	calibration.	For	example,	Liou	et	al	developed	the	most	well	known	prediction	model	in	CF	that	includes	FEV1%	and	several	additional	clinical	features.5	They	assessed	model	fit,	and	concluded	that	their	model	was	more	accurate	than	FEV1%	alone	for	predicting	5-year	mortality.	However,	only	assessing	how	closely	the	model	fits	the	observed	data	is	not	sufficient	when	the	model	is	meant	for	classification.7-9	While	agreement	between	the	predicted	and	actual	numbers	of	deaths	represents	good	model	calibration,	it	does	not	necessarily	translate	to	good	classification	accuracy.10		Two	papers	have	evaluated	predicted	versus	actual	mortality,	Aaron	et	al11	and	Mayer-Hamblett	et	al.9	Aaron	et	al	compared	predicted	versus	actual	numbers	of	deaths	and	concluded	that	their	model	was	accurate	for	prediction	of	one-year	survival.	Mayer-Hamblett	et	al,	however,	addressed	appropriate	evaluation	of	their	model	using	
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classification	error	rates,	i.e.	sensitivity	and	specificity,	for	classifying	subjects	based	on	2-year	mortality.	They	showed	that	their	multivariate	model	did	not	perform	better	than	FEV1%	alone,	and	that	both	are	inadequate	for	use	in	practice.	They	concluded:	“better	clinical	predictors	of	short-term	mortality	among	patients	with	CF	are	needed.”		In	addition	to	classification	error	rates,	appropriate	evaluation	of	a	risk	model	must	account	for	time-varying	measurements.	In	practice,	key	clinical	parameters	included	in	the	lung	allocation	score	(LAS)	are	updated	at	routine	care	visits	and	then	used	to	guide	decisions	regarding	listing	status	in	the	US.	Interestingly,	the	utility	of	updating	markers	has	never	been	empirically	evaluated.	We	assess	time-varying	accuracy	using	appropriate	time-dependent	classification	error	rates.	Such	evaluation	could	also	help	assess	how	often	patient	information	such	as	FEV1%	should	be	updated	in	practice	before	information	becomes	outdated	and	impacts	accuracy.		It	is	imperative	to	continue	to	develop	models	that	more	accurately	predict	survival	for	CF	patients.	Prior	studies	that	have	proposed	models	have	either	failed	to	evaluate	the	accuracy	of	survival	prediction,	or	have	been	limited	to	quantifying	model	accuracy	according	to	an	arbitrary	baseline	time	point	that	does	not	reflect	clinical	practice	where	physicians	update	predictions	as	clinical	parameters	change.	The	primary	objective	of	our	work	is	to	apply	a	novel	statistical	tool	for	evaluating	the	accuracy	of	survival	models	in	CF,	importantly	-	and	unlike	prior	evaluations	-	accounting	for	the	potentially	time-varying	predictions	based	on	routinely	updated	clinical	assessments.		Application	of	the	tool	for	evaluating	existing	published	survival	models	in	CF	is	presented,	in	addition	to	a	demonstration	of	how	the	tool	can	be	utilized	to	identify	subgroups	of	CF	patients	for	whom	prediction	of	survival	is	more	reliable.					
METHODS	
Study	cohort	We	used	the	Cystic	Fibrosis	Foundation	(CFF)	National	Patient	Registry	(CFFPR)	data,	which	consists	of	all	patients	who	agreed	to	participate	in	the	CF	Registry	and	who	were	seen	in	a	CFF-accredited	care	center	in	the	US	from	1986	through	2012.		The	CFFPR	obtains	written	and	informed	consent	from	each	participant.	This	analysis	was	approved	by	the	CFFPR	oversight	committee	and	was	granted	Institutional	Review	Board	Exempt	Status	by	
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the	University	of	Washington	Human	Subjects	Division	(due	to	being	anonymized	data).	We	selected	the	prevalent	subjects	in	1993	as	our	study	cohort	to	match	the	analysis	of	Liou	et	al.5	Our	study	cohort	consisted	of	17,926	prevalent	CF	cases	on	January	1,	1993.	We	treated	the	measurements	available	on	this	date	as	baseline	FEV1%	measurements.	6,028	subjects	were	excluded	due	to	missing	baseline	FEV1%	measurements	(of	these,	3,507	were	younger	than	5.5	years	at	baseline).	After	exclusions,	11,254	patients	remained	in	the	study	cohort;	3,906	(35%)	of	these	patients	were	observed	to	die	during	the	study	period	ending	on	December	31,	2011.	2,414	subjects	were	recipients	of	lung	transplantation	between	1993	and	2011;	we	censored	these	subjects	at	the	time	of	transplantation.			For	each	patient,	we	had	baseline	demographic	and	diagnosis	data	and	approximately	annual	measurements	of	FEV1%.	Counting	multiple	observations	per	patient,	we	included	140,651	total	annual	records.	Of	these,	16,846	had	missing	FEV1%	measurements.	We	imputed	missing	values	by	carrying	forward	the	last	non-missing	value	for	that	patient.		
	
Risk	models		FEV1%	of	predicted	is	a	standard	measure	used	in	practice	to	guide	recommendation	for	lung	transplantation.	We	evaluated	the	following	models:	(i)	a	base	model	containing	only	FEV1%	and	(ii)	a	multivariate	model	consisting	of	FEV1%,	age,	gender,	weight,	pancreatic	sufficiency,	Staphylococcus	aureus	infection,	and	Burkholderia	cepacia	infection.5	Predictions	from	Cox	models	were	summarized	into	a	single	baseline	risk	score	and	a	separate	time-varying,	updated	risk	score.	For	the	baseline	score,	we	used	10-fold	cross-validation	to	protect	against	overfitting.	For	the	time-varying	score,	we	used	baseline	measurements	as	training	data	to	develop	the	Cox	model	and	predicted	the	score	at	follow-up	times	using	updated	values	of	FEV1%.	We	added	flexibility	to	both	models	by	using	cubic	splines	to	model	continuous	variables.		
	
	
	
	
6	
Evaluation	of	model	accuracy	Diagnostic	accuracy:	classification	error	rates	The	traditional	diagnostic	classification	problem	is	based	on	a	binary	outcome,	typically	the	presence	or	absence	of	disease.	Mayer-Hamblett	et	al9	assessed	prognostic	accuracy	by	defining	a	yes/no	outcome	for	death	within	2	years	from	baseline.	Classification	errors	include	false	negatives,	i.e.	patients	who	were	predicted	by	the	risk	score	to	survive	for	longer	than	two	years	were	observed	to	die	within	two	years,	and	conversely,	false	positives,	i.e.	healthier	subjects	who	did	survive	beyond	two	years	were	predicted	to	die	within	two	years.	Minimizing	these	errors	is	equivalent	to	maximizing	the	sensitivity	(or	true	positive	fraction	(TPF))	and	specificity	(or	1	-	false	positive	fraction	(FPF)),	respectively.	The	Receiver	Operating	Characteristic	(ROC)	curve	is	a	standard	tool	that	plots	TPF	versus	FPF	for	all	possible	risk	score	cut-offs.12-16	The	ROC	curve	is	commonly	summarized	using	the	area	under	the	ROC	curve	(AUC),	ranging	from	0.5	to	1.0,	which	indicate	no	discrimination	to	perfect	discrimination.	The	AUC	is	also	a	concordance	statistic	and	represents	the	probability	that	a	randomly	chosen	subject	who	dies	(case)	has	a	higher	marker	value	than	a	randomly	chosen	subject	who	survives	(control).		Time-varying	prognostic	accuracy	Implicit	in	the	use	of	traditional	diagnostic	TPF	and	FPF	are	current-status	definitions	of	disease.	Since	we	are	interested	in	a	setting	where	outcome	status	changes	with	time,	precise	definitions	are	necessary	to	include	event	timing	in	definitions	of	prognostic	error	rates.	Time-dependent	ROC	curve	methods	that	extend	concepts	of	sensitivity	and	specificity	and	characterize	prognostic	accuracy	for	survival	outcomes	have	been	proposed	in	the	statistical	literature	and	now	widely	adopted	in	practice.17,18		To	evaluate	both	baseline	and	time-varying	measurements,	we	use	the	incident-case	definitions	of	Heagerty	&	Zheng,	which	are	based	on	a	binary	classification	of	the	risk	set	at	any	time	t.18	That	is,	among	the	patients	who	are	still	alive	at	time	t,	cases	are	defined	as	those	who	die	at	t	and	controls	as	those	who	survive	beyond	t.	The	sensitivity	and	specificity	at	time	t	are	the	error	rates	in	classifying	subjects	at	that	time,	and	can	be	summarized	using	a	time-dependent	ROC	curve.	The	time-dependent	AUC,	or	AUC(t),	is	then	defined	as	the	area	under	the	time-dependent	ROC	curve	and	interpreted	as	the	
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probability	that	a	randomly	chosen	case	who	dies	at	time	t	has	a	higher	marker	value	than	a	randomly	chosen	control	who	survives	beyond	time	t.	These	definitions	are	appropriate	for	evaluating	the	performance	of	a	baseline	or	time-varying	marker	in	the	CF	lung	transplantation	setting,	as	interest	lies	in	identifying	patients	who	are	at	the	highest	risk	of	death	in	the	near	future,	so	that	they	may	be	given	priority	for	limited	donor	organs.	The	recipient	decision	may	be	made	at	multiple	time	points	as	donor	organs	become	available,	but	is	always	only	applicable	to	those	subjects	who	remain	alive	at	those	times.	We	estimated	the	time-dependent	AUC	using	a	simple	nonparametric	rank-based	approach.19	The	idea	behind	this	approach	is	to	compute	for	each	risk	set	the	binary	concordance	statistic	using	only	the	individual	case	and	associated	risk-set	controls.	For	a	fixed	time	t,	we	calculate	a	percentile	for	each	case	in	the	risk	set	relative	to	the	controls	in	the	risk	set.	A	perfect	marker	would	have	the	case	value	greater	than	100%	of	risk	set	controls.	The	mean	percentile	at	time	t	is	calculated	as	the	mean	of	the	percentiles	for	all	cases	in	a	window	around	t.	The	summary	curve,	AUC(t),	is	then	estimated	as	the	local	average	of	case	percentiles.	This	nonparametric	approach	provides	both	a	simple	description	for	marker	performance	within	each	risk	set	and	by	smoothing	individual	case	percentiles,	a	final	summary	curve	over	time	characterizes	how	accuracy	may	be	changing	over	time.	Although	the	AUC	is	a	standard	measure	of	accuracy,	it	summarizes	the	sensitivity	of	a	risk	score	over	the	entire	range	of	specificities	from	0	to	100%.	In	contrast,	clinical	decisions	are	typically	made	based	on	a	single	risk	score	cut-off	that	has	been	shown	to	perform	with	high	sensitivity	and/or	high	specificity.	Therefore,	in	evaluating	a	risk	score’s	performance	and	its	impact	for	treatment	decisions,	it	is	important	to	also	assess	the	sensitivity	at	a	fixed	high	specificity.	Using	the	above	methods,	we	obtained	a	summary	curve	of	sensitivity	or	TPF	for	a	fixed	specificity	of	95%	or	FPF	of	5%.		Finally,	we	assessed	the	time-varying	prognostic	accuracy	of	time-varying,	or	updated,	risk	scores	using	an	extension	of	the	approach	of	Saha-Chaudhuri	&	Heagerty19	to	accommodate	time-varying	markers	(Heagerty,	Bansal,	Saha-Chaudhuri	et	al.,	2015,	unpublished	manuscript).	At	any	time	t,	the	last	measured	value	of	the	risk	score	was	used	as	the	current	risk	prediction.	
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Stratification	by	Risk	Group	We	evaluated	the	performance	of	annually	updated	FEV1%	measurements	in	subgroups	defined	by	baseline	FEV1%	(FEV1%	≤	30	versus	FEV1%	>	30),	baseline	age	(≤11	years,	12-17	years,	and	≥18	years),	gender,	and	F508	genotype.	
	
RESULTS	
Cohort	characteristics	Table	1	summarizes	the	characteristics	of	the	study	cohort.	Patients	who	died	earlier	also	tended	to	be	older	at	baseline,	have	lower	FEV1%,	be	in	lower	weight	and	height	percentiles,	be	slightly	less	likely	to	have	Staphylococcus	aureus	infection	and	slightly	more	likely	to	have	Burkholderia	cepacia	infection.	 		 	
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Table	1:	Summary	of	baseline	(1993)	subject	characteristics		 Overall	(n	=	11,254)	 Died	within	1	year	(n	=	287)	
Died	1-5	years	(n	=	1,077)	 Survived	at	least	5	years	(n	=	9,146)	Age	on	Dec	31,	1992,	Mean	(SD)	 18.0	(8.9)	 24.2	(9.6)	 22.0	(9.2)	 16.9	(8.5)	Sex,	n	(%)	
• Female	
• Male	
	5,187	(46%)	6,067	(54%)	
	144	(50%)	143	(50%)	
	529	(49%)	548	(51%)	
	4,185	(46%)	4,961	(54%)	Race,	n	(%)	
• White	
• African	American	
• Other	
	10,858	(96%)	320	(3%)	76	(1%)	
	281	(98%)	6	(2%)	0	(0%)	
	1,031	(96%)	40	(4%)	6	(1%)	
	8,819	(96%)	259	(3%)	68	(1%)	Genotype,	n	(%)	
• ΔF508	homozygous	
• ΔF508	heterozygous	
• Other	
• Missing	
	4,346	(39%)	3,139	(28%)	883	(8%)	2,886	(26%)	
	55	(19%)	31	(11%)	11	(4%)	190	(66%)	
	281	(26%)	165	(15%)	63	(6%)	568	(53%)	
	3,856	(42%)	2,819	(31%)	742	(8%)	1,729	(19%)	FEV1%,	Mean	(SD)	 68.5	(28.0)	 32.4	(19.2)	 40.8	(20.1)	 74.5	(25.4)	Weight	percentile,	Mean	(SD)	 28.5	(26.6)	 8.7	(16.1)	 12.4	(18.5)	 30.5	(26.6)	Height	percentile,	Mean	(SD)	 29.3	(26.3)	 17.5	(23.0)	 19.1	(22.4)	 30.6	(26.5)	
Staphylococcus	aureus	status,	n	(%)	
• Yes	
• No	
• Not	cultured	
		3,001	(27%)		7,014	(62%)				1,239	(11%)	
		42	(15%)	234	(82%)	11	(4%)	
		242	(22%)		793	(74%)	42	(4%)	
		2,559	(28%)	5,468	(60%)	1,119	(12%)	
Burkholderia	cepacia	status,	n	(%)	
• Yes	
• No	
• Not	cultured	
		346	(3%)	9,669	(86%)				1,239	(11%)		
		33	(11%)		243	(85%)		11	(4%)		
		88	(8%)		947	(88%)			42	(4%)		
				195	(2%)	7,832	(86%)	1,119	(12%)		
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Assessment	of	time-varying	prognostic	accuracy	of	base	model	using	baseline	and	
updated	measurements	Figure	1(a)	shows	the	estimated	AUC(t)	or	mean	percentile	for	FEV1%	baseline	and	annually	updated	measurements.	Not	surprisingly,	the	performance	of	a	baseline	FEV1%	measurement	declines	over	time,	from	0.87	(95%	CI	(0.84,	0.88))	at	baseline	(1993)	to	0.62	(95%	CI	(0.59,	0.65))	20	years	later	(2012).	In	contrast,	an	annually	updated	FEV1%	consistently	maintains	an	AUC	of	approximately	0.90	over	time.	Although	AUC=0.90	is	typically	considered	to	be	excellent	performance,	it	does	not	translate	to	FEV1%	having	adequate	performance	in	this	setting.	90th	percentile	means	that	out	of	100	patients	on	the	wait-list,	the	case	marker	value	is	higher	than	90	control	marker	values;	however,	it	also	means	that	9	other	controls	will	be	prioritized	ahead	of	the	case.	Figure	1(b)	shows	the	TPF	for	a	fixed	FPF	of	5%.	Again,	an	annually	updated	FEV1%	has	better	performance	than	baseline	FEV1%;	however,	a	TPF	of	45%	is	likely	inadequate	for	clinical	practice.	FEV1%	alone	does	not	have	satisfactory	performance.	We	also	assessed	the	performance	of	a	multivariate	model	that	combined	FEV1%	with	a	number	of	clinical	variables.	We	note	that	this	model	is	very	similar	to	Liou	et	al’s	model5,	which	they	proposed	as	a	better	predictor	of	mortality,	with	the	exception	that	our	model	excluded	diabetes	mellitus	and	number	of	acute	exacerbations,	as	we	did	not	have	data	on	these	variables	for	this	analysis.	Figure	2	confirms	the	findings	of	Mayer-Hamblett	et	al9	and	shows	that	adding	clinical	variables	to	the	FEV1%	base	model	does	not	improve	performance	beyond	using	FEV1%	alone,	using	baseline	or	updated	measurements.		Finally,	an	assessment	of	the	performance	of	annually	updated	FEV1%	measurements	compared	to	those	updated	every	2	years	shows	slightly	worse	performance	of	the	latter	in	even	years	when	the	measurement	is	a	year	old.	Performance	in	odd	years	is	exactly	the	same,	since	FEV1%	is	always	updated	in	those	years	(table	available	in	online	supplemental	material).				 	
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	Figure	1:	Time-varying	performance	of	baseline	versus	updated	FEV1%	measurements,	using	(a)	AUC,	and	(b)	sensitivity	at	a	fixed	specificity	of	95%.	Dotted	lines	represent	95%	confidence	bands.		 	
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	Figure	2:	Performance	of	FEV1%	alone	compared	to	a	multivariate	model	combining	FEV1%	with	other	clinical	variables,	time-varying	measurements	(top	curves)	and	baseline	measurements	(bottom	curves).	Dotted	lines	represent	95%	confidence	bands.		
Stratification	by	risk	group	Figure	3	presents	Kaplan-Meier	survival	curves	for	subgroups	defined	by	baseline	FEV1%,	baseline	age,	gender,	and	F508	genotype.	We	see	a	large	gap	in	survival	probabilities	by	baseline	FEV1%.	Patients	with	FEV1%≤30	have	poor	prognosis,	with	an	estimated	5-year	survival	probability	of	35%,	compared	to	90%	in	the	FEV1%>30	subgroup.	The	second	panel	shows	worse	survival	with	increasing	age,	with	estimated	5-year	survival	probabilities	of	95%,	87%	and	76%	in	the	≤11	years,	12-17	years,	and	≥18	years	subgroups,	respectively.	Gender	and	F508	genotype	have	little	impact	on	survival	probabilities.	This	result	regarding	F508	genotype	is	likely	due	to	the	low	rate	of	genotyping	in	this	cohort	(66%	of	the	patients	who	died	within	one	year	were	not	genotyped).
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	Figure	3:	Kaplan-Meier	survival	curves	by	subgroup	
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Figure	4	shows	the	predictive	accuracy	of	FEV1%	in	the	same	subgroups.	The	performance	of	FEV1%	in	each	subgroup	seems	to	be	largely	determined	by	the	prognosis	in	that	subgroup.	FEV1%	has	poorer	predictive	performance	in	subgroups	with	poorer	survival,	where	it	is	likely	that	a	patient’s	prognosis	is	dominated	by	other	factors	that	are	not	captured	by	FEV1%.		 	
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	Figure	4:	Performance	of	time-varying	FEV1%	measurements	by	subgroups	based	on:	(a)	FEV1%,	(b)	age,	(c)	sex	and	(d)	F508	mutation
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DISCUSSION	Commonly	used	measures	of	model	fit	and	calibration	are	insufficient	for	evaluating	risk	prediction	models	in	CF	when	the	goal	is	to	prioritize	patients	for	lung	transplantation	and	when	a	patient’s	clinical	status	is	changing	over	time.	Therefore,	we	presented	an	approach	that	uses	time-dependent	classification	error	rates	that	can	be	used	to	characterize	the	potential	performance	of	a	survival	model,	while	accounting	for	the	time-varying	nature	of	the	prediction	itself.	In	the	CF	setting,	we	found	that	updated	measurements	of	FEV1%	have	consistent	performance	over	time,	whereas	the	performance	of	a	baseline	measurement	declines	over	time.	Thus,	previously	reported	estimates	of	the	accuracy	of	FEV1%	alone	do	not	capture	its	true	performance	in	a	clinical	setting.		It	is	clear	that	patient	information	should	be	updated	over	time	to	maintain	classification	accuracy;	however,	it	is	also	evident	that	neither	FEV1%	alone	nor	existing	multivariate	models	are	adequate	for	use	in	practice.		Being	able	to	evaluate	a	model’s	time-varying	accuracy	may	also	help	guide	clinical	practice	and	policy	with	regards	to	the	frequency	of	updating	patient	information.	A	comparison	of	1-year	versus	2-year	measurements	of	FEV1%,	for	example,	showed	minor	differences	in	performance.	A	limitation	of	the	analysis	is	that	it	was	done	in	an	older	cohort,	in	order	to	compare	performance	with	Liou	et	al’s	model5.	A	more	up-to-date	cohort	could	change	the	results,	but	it	would	not	take	away	from	the	key	point	–	that	time-varying	approaches	are	better	than	the	traditional	approaches	currently	used	in	CF.	In	conclusion,	we	found	that	using	a	statistical	evaluation	approach	that	is	closely	tied	to	the	clinical	goal	of	using	predicted	risk	as	a	score	to	rank	patients	as	a	function	of	time	can	significantly	change	the	conclusions	drawn	about	a	risk	prediction	model’s	performance.	As	new	models	are	developed,	perhaps	incorporating	novel	biomarkers,	the	proposed	approach	could	be	used	to	accurately	assess	their	predictive	ability.	As	shown,	standard	methods	may	underestimate	their	performance	by	not	capturing	how	these	models	will	be	used	dynamically	within	the	clinical	setting.	We	note	that	our	focus	here	is	on	risk	prediction	models,	assuming	that	patients	are	added	to	a	lung	transplantation	wait-list	based	on	their	expected	benefit	from	transplantation.	In	practice,	any	risk	prediction	should	be	coupled	with	assessments	of	treatment	benefit.		
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SUPPLEMENTARY	MATERIAL		 Table:	One-year	average	performance	of	annually	updated	FEV1%	measurements	compared	to	FEV1%	measurements	updated	every	2	years.	Performance	in	odd	years	is	exactly	the	same	between	the	two	measures,	since	both	are	updated	in	those	years.	
Year	 Annually	updated	 Updated	every	2	years	 Difference	1993	–	1994	 0.87	 0.87	 0	1994	–	1995	 0.87	 0.85	 -0.02	1995	–	1996	 0.88	 0.88	 0	1996	–	1997	 0.86	 0.84	 -0.02	1997	–	1998	 0.89	 0.89	 0	1998	–	1999	 0.87	 0.85	 -0.02	1999	–	2000	 0.85	 0.85	 0	2000	–	2001	 0.89	 0.85	 -0.04	2001	–	2002	 0.86	 0.86	 0	2002	–	2003	 0.87	 0.85	 -0.02	2003	–	2004	 0.86	 0.86	 0	2004	–	2005	 0.85	 0.82	 -0.03	2005	–	2006	 0.84	 0.84	 0	2006	–	2007	 0.82	 0.80	 -0.02	2007	–	2008	 0.83	 0.83	 0	2008	–	2009	 0.83	 0.80	 -0.03	2009	–	2010	 0.83	 0.83	 0	2010	–	2011	 0.82	 0.79	 -0.03	2011	–	2012	 0.81	 0.81	 0				
